FNY Investment Advisers LLC bought a new stake in shares of argenx SE – (NASDAQ:ARGX) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,000 shares of the company’s stock, valued at approximately $374,000.
Other hedge funds have also added to or reduced their stakes in the company. We Are One Seven LLC bought a new position in shares of argenx during the 4th quarter valued at $27,000. Partner Investment Management L.P. bought a new stake in argenx in the 4th quarter worth $110,000. Virtu Financial LLC bought a new stake in argenx in the 1st quarter worth $217,000. JGP Global Gestao de Recursos Ltda. bought a new stake in argenx in the 4th quarter worth $202,000. Finally, Brown Advisory Securities LLC bought a new stake in argenx in the 4th quarter worth $217,000. 63.72% of the stock is currently owned by institutional investors.
NASDAQ:ARGX opened at $115.00 on Thursday. argenx SE – has a 12 month low of $63.81 and a 12 month high of $135.58. The stock has a market capitalization of $3.87 billion, a PE ratio of -48.94 and a beta of 1.23.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Article: Back-End Load
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.